Skip to content

Liabilities & Structure

This interactive dashboard combines a liabilities grid with a 3D structural viewer.

This analysis gives residue-level detail of the liabilities that were detected in the sequence(s) of the antibody. The liabilities are categorized by type and severity level. The severity level is determined by the potential impact of the modification on the antibody's stability, aggregation, or PTMs. Evaluation of the severity and structure position of the liabilities is critical for determining the best strategy for engineering the antibody to improve its developability.

Engineering of strong stability violations has been shown to improve the developability of antibodies.

  • Kerwin et al., "Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity." Journal of Pharmaceutical Sciences (2020).
  • Williams et al., "A candidate antibody drug for prevention of malaria." Nature Medicine (2024)
  • Sajadi et al., "A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV." Structure (2025)

Features

  • Data Grid: Lists every detected liability (e.g., Deamidation sites, Unpaired Cysteines).
    • Start/End positions.
    • Severity Level (High/Med/Low).
    • Liability Type.
  • Engineering Mutation Designs: Click a liability to enter a mutation design used by the Engineering tab.
  • Observations: Click a liability to enter an observation for that IMGT position. These are displayed in the Observations tab and on a clicked residue.
  • 3D Viewer: If a PDB is associated, clicking Show 3D View will display the structure with frameworks, CDRs, and liabilities highlighted. Note - only a singe entry should be selected before launching the Liabilities tab to use this feature.
  • Export

Liabilities & Structure

References

  • The PDB structure viewer is provided by Mol*.